The association of hypertension and diabetes: Prevalence, cardiovascular risk and protection by blood pressure reduction

Acta Diabetologica

Volumn 42, Issue SUPPL. 1, 2005, Pages

  Mancia, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Angiotensin II receptor blockers; Antihypertensives; Calcium channel blockers; Cardiovascular risk; Diabetes; Diuretics

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; RESERPINE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTOREGULATION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; STROKE; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION;

EID: 18744388334     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00592-005-0177-z     Document Type: Article

References (56)

1. American Diabetes Association (2004) Hypertension management in adults with diabetes. Diabetes Care 27[Suppl 1]:S65-S67
2. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342:905-912
3. The Hypertension in Diabetes Study Group (1993) Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11:309-317
4. Colhoun HM, Dong W, Barakat MT, Mather HM, Poulter NR (1999) The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabet Med 16:35-40
5. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH (1994) Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17:1247-1251
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289:2560-2572
7. Guidelines Committee (2003) 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053
8. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
9. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J (1996) Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886-1892
10. UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-720
11. Borrello F, Beahan M, Klein L, Gheorghiade M (2003) Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period. Rev Cardiovasc Med 4[Suppl 3]:S13-S24
12. Malmberg K, Herlitz J, Hjalmarson A, Ryden L (1989) Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 10:423-428
13. Sleight P (1987) Beta blockade early in acute myocardial infarction. Am J Cardiol 60:6A-10A
14. Gundersen T (1985) Secondary prevention after myocardial infarction: subgroup analysis of patients at risk in the Norwegian Timolol Multicenter Study. Clin Cardiol 8:253-265
15. Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489-497
16. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
17. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652
18. Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086-1097
19. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340:677-684
20. Zanchetti A, Hansson L, Menard J, Leonetti G, Rahn KH, Warnold I, Wedel H (2001) Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. J Hypertens 19:819-825
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290:2805-2816
22. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762
23. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419
24. Tooke JE (1995) Microvascular function in human diabetes. A physiological perspective. Diabetes 44:721-726
25. Heagerty AM (1997) Significance of structural changes in small arteries in hypertension. Blood Press 2[Suppl]:31-33
26. Frattola A, Parati G, Castiglioni P, Paleari F, Ulian L, Rovaris G, Mauri G, Di Rienzo M, Mancia G (2000) Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension 36:622-628
27. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, Grassi G, Di Rienzo M, Pedotti A, Zanchetti A (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96-104
28. Mancia G, Omboni S, Grassi G (1997) Combination treatment in hypertension: the VeraTran Study. Am J Hypertens 10[7 Pt 2]:153S-158S
29. Fenton C, Keating GM, Scott LJ (2003) Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. Drugs 63:2013-2026
30. Mancia G, Grassi G (2002) Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20:1461-1464
31. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
32. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004-1010
33. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366-372
34. Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179
35. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
36. Zanchetti A, Ruilope LM (2002) Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 20:2099-2110
37. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A (2001) Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker- based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 24:2091-2096
38. Lim PO (1999) CAPPP trial. Captopril Prevention Project. Lancet 353:1793-1796
39. The ALLHAT Officers and Coordinators (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997
40. Weber MA (2003) The ALLHAT report: a case of information and misinformation. J Clin Hypertens 5:9-13
41. Giannattasio C, Failla M, Piperno A, Grappiolo A, Gamba P, Paleari F, Mancia G (1999) Early impairment of large artery structure and function in type I diabetes mellitus. Diabetologia 42:987-994
42. National Kidney Foundation (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43:S1-S290
43. Fleischmann EH, Schmieder RE (2002) Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr Cardiol Rep 4:474-478
44. Schiffrin EL, Park JB, Integan HD, Touyz RM (2000) Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101:1653-1659
45. Struthers AD, Murphy MB, Dollery CT (1985) Glucose tolerance during antihypertensive therapy in patients with diabetes mellitus. Hypertension 7:95-101
46. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886
47. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O (2003) Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21:1563-1574
48. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356:359-365
49. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with hypertension-2 study. Lancet 354:1751-1756
50. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022-2031
51. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM - Overall programme. Lancet 362:759-766
52. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC (2003) Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107:1291-1296
53. Alderman MH, Cohen H, Madhavan S (1999) Diabetes and cardiovascular events in hypertensive patients. Hypertension 33:1130-1134
54. Dunder K, Lind L, Zethelius B (2003) Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 326:681-688
55. McFarlane SI, Kumar A, Sowers JR (2003) Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91:30H-37H
56. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators (2004) Rationale, design and baseline characteristics of two large, simple randomized trials evaluation telmisartan, ramipril and their combination in high-risk patients: the ONTARGET/TRANSCEND trials. Am Heart J 148:52-61